Oncolytics Biotech Inc T.ONC

Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

[Noteable]

Seagen retained Centerview Partners LLC (“Centerview”) as financial advisor to the Board in connection with the merger and the other transactions contemplated by the merger agreement. 

Background of the Merger - Page 33

https://d18rn0p25nwr6d.cloudfront.net/CIK-0001060736/1e7d9948-6569-44a4-ad58-1d1ae6840511.pdf#page40

[Noteable]

Calling this Background information as either same old garbage or a pump, is really stretching things far beyond someone's understanding of these matters.

[Angler101]

All those who are worried about the share price, and/or griping or whining about it, I get it.....but you seem to forget that there are 5 analysts(so far) following this stock and 3 are calling it a strong buy while the other two probably soon will be as well......with price targets anywhere from what?.....8 to 15 bucks.....not to mention we’ve just had trial results that were referred to as being

[fox7mf]

I think everybody has had infinite amounts of patience. Where's an update on mBC? Very quiet where that indication is concerned. Where and when for a BD deal? Partnership or buyout or anything?

[Noteable]

May 15, 2023 - Pfizer and Seagen on Friday submitted paperwork for their proposed $43 billion merger to the Federal Trade Commission and the Department of Justice (FTC). Friday’s premerger filing kicks off a 15-day waiting period based on the FTC’s rules for a cash tender offer. The two companies can proceed with the transaction if the waiting period expires without any objections

[Noteable]

July 18, 2023 - " The Federal Trade Commission has requested additional information on Pfizer’s proposed acquisition of Seagen, the cancer-focused biotech revealed in a Securities and Exchange Commission filing posted Friday.  In the SEC document, Seagen disclosed that the FTC’s request will further extend the waiting period, as mandated by the Hart-Scott-Rodino

[Noteable]

" Second requests from the FTC come in roughly 25% of merger and acquisition deals, with the regulator challenging a transaction 5% to 10% of the time, MEDACorp told SVB, adding that a second request can extend the timeline for review by six to nine months.  A month ago, Pfizer revealed in an SEC filing that it had withdrawn its notification for the buyout of Seagen and

[Noteable]

July 20, 2023 - FTC and DOJ Release New Draft Merger Guidelines "The draft outlines 13 principles for reviewing merger analysis, with one key principle stating that mergers should not substantially increase concentration in already highly saturated markets." " ..the new guidelines released by the FTC and DOJ cover both horizontal and vertical mergers and represent a significant

[Noteable]

July 24, 2024 -  Amgen’s lupus pursuits have encountered another pitfall, this time via recently-purchased Horizon Therapeutics.  What may be a trip up for Horizon is also a gut punch for Amgen, in light of the fact that the California pharma’s lupus ambitions have yet to pan out. After the first quarter of the year, Amgen cut two lupus programs due to futility.  https:/

[Noteable]

July 25, 2023 -   FTC withdraws advocacy for pharmacy benefit managers "Claiming that its old policy statements no longer reflect current market dynamics, the Federal Trade Commission has voted to rescind its prior statements of advocacy for pharmacy benefit managers, effectively ending the agency's previously stated endorsement of PBMs. According to the FTC, the

[fasttrack5]

And this has what effect on Onolytics (ONC) ???

[Noteable]

" FTC withdraws advocacy for pharmacy benefit managers"  The positive impact will be on IV administered biological drugs prescribed and dispensed through hospital and oncologists offices in the United States.  https://www.healthcarefinancenews.com/news/ftc-withdraws-advocacy-pharmacy-benefit-managers

[Noteable]

"The American Pharmacy Cooperative approved of the FTC's move, saying it had long advocated for federal oversight of PBMs." [ All positive for the distribution and dispension of ONCY's pelareorep also because Big Pharma's acquisition of ONCY and pelareorep would not be considered as anticompetitive as is the FTC's view of the Amgen / Horizon US$27 Billion merger and very

[fox7mf]

Just for argument sake, what if Oncy was offered just north of the Immunomedics buyout, say $22b...should we expect FTC intervention?

[jimsenior]

@fox. A good question. it may not be the amount of money but the potential extensive reach of pela that might prompt a look. We are vulnerable for the next little while and these players are relentless. Would like to have added a few in here, but upcoming expenses do not allow. A little annoyed and holding strong.

[Noteable]

Pelareorep does not have any "product bundling" issues, since combination therapies for one indication are different from "bundling" different drugs with different indications being offered to wholesalers under the "take one and then take all" marketing / retailing scheme that Amgen has been noted for. "In its suit, the FTC argues that Amgen could

[jimsenior]

@Noteable.  Thank you for clearing up these issues. We wait.

[westcoast1000]

Replying to Jimsenior, if ONCY and pela proves to have such widespread reach and unique benefits in combos, then the future BP owner may be forced by the FTC to make it available through license to its competitors. It would then be like a common carrrier, or common adjuvant aid, similar to how electric utilities must license their line capacity to their competitors to avoid being anti-competitive.

[Noteable]

This question has already been answered, as has been the question about anti-competitiveness guidelines. Effectively FTC scrutiny has been interested in M&A deals valued over US$25 Billon, and because of the anticompetitive bundling concerns in the Amgen/Horizon merger, the FTC has taken issue with this US$ 27.5 Billion deal  

[westcoast1000]

Responding to Fox's question about FTC review of a large ONCY buyout, I do not think such a buy-out would raise any anti-competitive concerns. We do not have any sales at present, so market power for sales in a given indication is not concentrated due to a buyout. The extreme example of a possible anti-competitive concern would be if one or two large companies already owned most of the